Cita APA

Braña Garcia, I., Shapiro, G. I., Trigo, J. M., Boni, V., Moreno, V., & Pistilli, B. (2022). Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: Results from a phase II basket study.

Citación estilo Chicago

Braña Garcia, Irene, G. I. Shapiro, José Manuel Trigo, Valentina Boni, Victor Moreno, y Barbara Pistilli. Lurbinectedin, a Selective Inhibitor of Oncogenic Transcription, in Patients With Pretreated Germline BRCA1/2 Metastatic Breast Cancer: Results From a Phase II Basket Study. 2022.

Cita MLA

Braña Garcia, Irene, et al. Lurbinectedin, a Selective Inhibitor of Oncogenic Transcription, in Patients With Pretreated Germline BRCA1/2 Metastatic Breast Cancer: Results From a Phase II Basket Study. 2022.